{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:45:11Z","timestamp":1791359111447,"version":"4.3.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.psychres.2019.112602","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T11:00:30Z","timestamp":1570186830000},"page":"112602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder"],"prefix":"10.1016","volume":"282","author":[{"given":"Atieh","family":"Modarresi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Chaibakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Koulaeinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram Rafieian","family":"Koupaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2019.112602_bib0001","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/JCP.0b013e318192e9a4","article-title":"Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial","volume":"29","author":"Aboujaoude","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2019.112602_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00004714-200206000-00012","article-title":"Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder","volume":"22","author":"Ackerman","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2019.112602_bib0003","first-page":"976","article-title":"Topiramate augmentation in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Afshar","year":"2014","journal-title":"J. Res. Med. Sci."},{"key":"10.1016\/j.psychres.2019.112602_bib0004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-010-1808-9","article-title":"The role of nmda receptors in the signal attenuation rat model of obsessive-compulsive disorder","volume":"210","author":"Albelda","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2019.112602_bib0005","article-title":"Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study","author":"Amidfar","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.psychres.2019.112602_bib0006","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pneurobio.2004.02.004","article-title":"Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology","volume":"72","author":"Aouizerate","year":"2004","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.psychres.2019.112602_bib0007","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00213-004-1847-1","article-title":"Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study","volume":"174","author":"Arnold","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2019.112602_bib0008","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1742-1241.2009.02168.x","article-title":"Understanding heterogeneity in meta-analysis: the role of meta-regression","volume":"63","author":"Baker","year":"2009","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.psychres.2019.112602_bib0009","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0972-6748.132930","article-title":"An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder","volume":"22","author":"Bakhla","year":"2013","journal-title":"Ind. Psychiatry J."},{"key":"10.1016\/j.psychres.2019.112602_bib0010","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.biopsych.2012.05.028","article-title":"Effects of ketamine in treatment-refractory obsessive-compulsive disorder","volume":"72","author":"Bloch","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112602_bib0011","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0014-2999(89)90385-3","article-title":"Memantine is a potent blocker of N-methyl-d-aspartate (NMDA) receptor channels","volume":"166","author":"Bormann","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.psychres.2019.112602_bib0012","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2005.04.043","article-title":"Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial","volume":"58","author":"Coric","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112602_bib0013","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.4088\/JCP.v65n0803","article-title":"A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors","volume":"65","author":"Denys","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112602_bib0014","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin. Trials"},{"key":"10.1016\/j.psychres.2019.112602_bib0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jpsychires.2018.07.008","article-title":"Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: double-blind, randomized, placebo-controlled trial","volume":"104","author":"Farnia","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2019.112602_bib0016","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/WNF.0b013e3180314ae7","article-title":"An open-label, flexible-dose study of memantine in major depressive disorder","volume":"30","author":"Ferguson","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.psychres.2019.112602_bib0017","doi-asserted-by":"crossref","first-page":"81","DOI":"10.64719\/pb.4096","article-title":"Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial","volume":"42","author":"Feusner","year":"2009","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.psychres.2019.112602_bib0018","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","article-title":"Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study","volume":"47","author":"Ghaleiha","year":"2013","journal-title":"J. Psychiatr. Res"},{"key":"10.1016\/j.psychres.2019.112602_bib0019","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The yale-brown obsessive compulsive scale. I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112602_bib0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.54.1.142","article-title":"Altered cortical excitability in obsessive-compulsive disorder","volume":"54","author":"Greenberg","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.psychres.2019.112602_bib0021","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)","volume":"228","author":"Haghighi","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2019.112602_bib0022","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.psychres.2019.112602_bib0023","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/01.yic.0000199453.54799.cc","article-title":"Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder","volume":"21","author":"Hollander","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2019.112602_bib0024","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/WNF.0b013e318184fae2","article-title":"Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation","volume":"32","author":"Keck","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.psychres.2019.112602_bib0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3233\/JAD-180237","article-title":"Combination therapy of serotonin reuptake inhibitors and memantine for Obsessive- Compulsive Disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"64","author":"Kishi","year":"2018","journal-title":"J. Alzheimer's Dis. JAD"},{"key":"10.1016\/j.psychres.2019.112602_bib0026","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4088\/JCP.v66n0415","article-title":"Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation","volume":"66","author":"Koran","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112602_bib0027","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00213-005-0246-6","article-title":"N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder","volume":"184","author":"Lafleur","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2019.112602_bib0028","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4088\/JCP.v66n0610","article-title":"Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study","volume":"66","author":"Li","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112602_bib0029","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1176\/appi.ajp.159.2.263","article-title":"Symptom stability in adult obsessive-compulsive disorder: data from a naturalistic two-year follow-up study","volume":"159","author":"Mataix-Cols","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112602_bib0030","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/gps.939","article-title":"Memantine: update on the current evidence","volume":"18","author":"Mobius","year":"2003","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112602_bib0031","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-0043-120268","article-title":"Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial","volume":"51","author":"Modarresi","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psychres.2019.112602_bib0032","doi-asserted-by":"crossref","first-page":"b3244","DOI":"10.1136\/bmj.b3244","article-title":"The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study","volume":"339","author":"Nuesch","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.psychres.2019.112602_bib0033","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1017\/S1461145702002900","article-title":"Treatment non-response in OCD: methodological issues and operational definitions","volume":"5","author":"Pallanti","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2019.112602_bib0034","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jcpt.12370","article-title":"N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial","volume":"41","author":"Paydary","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.psychres.2019.112602_bib0035","first-page":"34","article-title":"Clinical treatment of obsessive compulsive disorder","volume":"2","author":"Pittenger","year":"2005","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.psychres.2019.112602_bib0036","first-page":"255","article-title":"[Anxiety disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association: diagnostic and statistical manual of mental disorders (DMS-IV \u2013 options book]","volume":"28","author":"Rabe-Jablonska","year":"1994","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.psychres.2019.112602_bib0037","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer's disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.psychres.2019.112602_bib0038","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4088\/JCP.15l10318","article-title":"Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion","volume":"77","author":"Rodriguez","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112602_bib0039","doi-asserted-by":"crossref","DOI":"10.1097\/JCP.0000000000000651","article-title":"Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial","author":"Sahraian","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2019.112602_bib0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JCP.0b013e3181c856de","article-title":"A single-blinded case-control study of memantine in severe obsessive-compulsive disorder","volume":"30","author":"Stewart","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2019.112602_bib0041","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/WNF.0000000000000029","article-title":"Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study","volume":"37","author":"Stryjer","year":"2014","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.psychres.2019.112602_bib0042","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/ije\/dyh300","article-title":"Investigating patient exclusion bias in meta-analysis","volume":"34","author":"Tierney","year":"2005","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.psychres.2019.112602_bib0043","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12888-014-0317-5","article-title":"Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"14","author":"Veale","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2019.112602_bib0044","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.pbb.2011.10.007","article-title":"The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder","volume":"100","author":"Wu","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.psychres.2019.112602_bib0045","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.pnpbp.2008.01.008","article-title":"A systematic review of off-label uses of memantine for psychiatric disorders","volume":"32","author":"Zdanys","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178119317810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178119317810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T16:44:36Z","timestamp":1786207476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178119317810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":45,"alternative-id":["S0165178119317810"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2019.112602","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2019.112602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112602"}}